Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).

Authors :: Stricker, Thomas
Jain, Neha
Yu, Elaine
Ma, Esprit
Schuldt, Robert
Wang, Rongrong
Sussell, Jesse
Ogale, Sarika
Szado, Tania
Price, Richard
Lin, Victor T. G.
Slater, Dennis
Vaena, Daniel A.
Staszewski, Harry
Fang, Bruno
Seneviratne, Lasika
Arrowsmith, Edward
Daniel, Davey B.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6507-6507, 1p
Publication Year :: 2023

Full Text Access

Tools